Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 14/20 | 0.43 |
| ▸ | CA2 | P00918 | 14/20 | 0.43 |
| ▸ | CA9 | Q16790 | 13/20 | 0.43 |
| ▸ | CA12 | O43570 | 12/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765847 | 0.82 | ADAM17 (0.46) | MMP13 | |
| SCHEMBL6705933 | 0.71 | POLB (0.39) | MMP13PTGS2 | |
| SCHEMBL6767486 | 0.67 | MEN1 (0.49) | CA1CA2CA9CA4MAPK1 | |
| SCHEMBL2019162 | 0.67 | HDAC1 (0.56) | MAPK1 | |
| SCHEMBL2024397 | 0.67 | KMT2A (0.60) | CA1CA9CA12 | |
| SCHEMBL31252762 | 0.67 | KMT2A (0.60) | CA1CA9CA12 | |
| SCHEMBL6767627 | 0.67 | GRM5 (0.43) | MMP13MAPK1 | |
| SCHEMBL6706809 | 0.66 | MMP13 (0.42) | MMP13 | |
| SCHEMBL20184098 | 0.66 | HDAC1 (0.52) | CA2CA9CA12 | |
| SCHEMBL6771059 | 0.66 | MAPK1 (0.42) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | MMP13 1/4885CA1 724/4885CA2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.